DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-1602]

Revocation of Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection of Antibodies against SARS-CoV-2, the Virus that Causes Coronavirus Disease 2019 (COVID-19)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocations of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Autobio Diagnostics Co. Ltd. (“Autobio”) for the Anti-SARS-CoV-2 Rapid Test (“Autobio’s Test”) and to Manufacturers and Other Stakeholders (“Stakeholders”) for certain in vitro diagnostic SARS-CoV-2 Antibody Tests. FDA revoked Autobio’s Authorization on August 6, 2020, and the Stakeholders’ Authorization on July 21, 2020, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, which include an explanation of the reasons for each revocation, are reprinted in this document.


ADDRESSES: Submit written requests for single copies of the revocations to the Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4338, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request or include a Fax number to which the

This document is scheduled to be published in the Federal Register on 10/05/2020 and available online at federalregister.gov/d/2020-21952, and on govinfo.gov
revocations may be sent. See the SUPPLEMENTARY INFORMATION section for electronic access to the revocations.

FOR FURTHER INFORMATION CONTACT: Jennifer J. Ross, Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 4332, Silver Spring, MD 20993-0002, 240-402-8155 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION:

I. Background

Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) allows FDA to strengthen the public health protections against biological, chemical, nuclear, and radiological agents. Among other things, section 564 of the FD&C Act allows FDA to authorize the use of an unapproved medical product or an unapproved use of an approved medical product in certain situations. On April 24, 2020, FDA issued an EUA for Autobio’s Anti-SARS-CoV-2 Rapid Test, subject to the terms of the Authorization. On April 28, 2020, FDA issued an EUA to Stakeholders, for certain in vitro diagnostic SARS-CoV-2 Antibody Tests (lateral flow or enzyme-linked immunosorbent assay tests to detect IgG only, IgG and IgM, or total antibodies in human plasma and/or serum) for use at laboratories certified under the Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. 263a, to perform moderate or high complexity tests. Notice of the issuance of the Authorizations was published in the Federal Register on July 14, 2020 (85 FR 42407), as required by section 564(h)(1) of the FD&C Act. Subsequent to the issuance of the Authorization for Autobio’s Test, FDA considered new information, including from an independent evaluation of Autobio’s Test from the National Institute of Health’s Frederick National Laboratory for Cancer Research, part of the National Cancer Institute (the “NCI study”), demonstrating performance below the performance information submitted in Autobio’s original EUA request.
and reflected in the authorized labeling for Autobio’s Test. Subsequent to the Stakeholders’ Authorization, FDA considered that no device had been listed under the EUA and that FDA may issue individual EUAs instead.

II. EUA Criteria for Issuance No Longer Met and Other Circumstances Make Revocation Appropriate to Protect the Public Health or Safety

Under section 564(g)(2)(B) and (C) of the FD&C Act, the Secretary of HHS may revoke an EUA if, among other things, the criteria for issuance are no longer met or other circumstances make such revocation appropriate to protect the public health or safety. On August 6, 2020, FDA revoked the EUA for Autobio’s Test because the criteria for issuance were no longer met and other circumstances make such revocation appropriate to protect the public health or safety. Under section 564(c)(2) of the FD&C Act, an EUA may be issued only if FDA concludes that, based on the totality of scientific evidence available, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing such disease or condition and that the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product.

Given the poor device performance observed in the NCI study since the issuance of the Authorization for Autobio’s Test, FDA has concluded it is not reasonable to believe the product may be effective in detecting antibodies against SARS-CoV-2 or that the known and potential benefits of the device outweigh its known and potential risks. In addition, based on the same information and the risks to public health from false test results, FDA has concluded under section 564(g)(2)(C) of the FD&C Act that other circumstances make revocation appropriate to protect the public health or safety. Accordingly, FDA has revoked EUA200349 for Autobio’s
Anti-SARS-CoV-2 Rapid Test, pursuant to section 564(g)(2)(B) and (C) of the FD&C Act. On July 21, 2020, FDA revoked the EUA for Stakeholders’ certain in vitro diagnostic SARS-CoV-2 Antibody Tests because other circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the FD&C Act), considering that no device has been listed under the EUA, and FDA can issue individual EUAs instead.

III. Electronic Access


IV. The Revocations

Having concluded that the criteria for revocation of the Authorizations under section 564(g) of the FD&C Act are met, FDA has revoked the EUAs for Autobio’s Anti-SARS-CoV-2 Rapid Test and Stakeholders’ certain in vitro diagnostic SARS-CoV-2 Antibody Tests. The revocations in their entirety follow and provide an explanation of the reasons for each revocation, as required by section 564(h)(1) of the FD&C Act.
August 6, 2020

Autobio Diagnostics Co. Ltd.
c/o Andre Hsing
Hardy Diagnostics
1430 West McCoy Lane
Santa Maria, CA 93455

Re: Revocation of EUA200349

Dear Mr. Hsing:

This letter is to notify you of the revocation of EUA200349, the Emergency Use Authorization (EUA) for Autobio Diagnostics Co. Ltd.'s (you, your, or Autobio's) Anti-SARS-CoV-2 Rapid Test, issued on April 24, 2020. The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360b-3) may, pursuant to section 564(g)(2)(B) and (C) of the Act, be revoked when the criteria in section 564(c) for issuance of such authorization are no longer met, or other circumstances make such revocation appropriate to protect the public health or safety. FDA has decided to revoke your EUA based on both of these grounds.

On April 24, 2020, FDA authorized the emergency use of Autobio's Anti-SARS-CoV-2 Rapid Test for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human plasma from anticoagulated blood (Heparin/EDTA/sodium citrate) or serum as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The authorized labeling for your test included clinical performance estimates, for all samples collected regardless of time since symptom onset, of 85.43% (346/405) positive percent agreement (PPA) for IgM, 86.17% (349/405) PPA for IgG, 88.15% (357/405) PPA for combined IgM/IgG, and 99.04% (309/312) negative percent agreement (NPA) for combined IgM/IgG. For samples collected 15 or more days after onset of symptoms, the performance estimates were 95.7% (289/302) PPA for IgM, 99.0% (299/302) PPA for IgG, and 99.0% (299/302) PPA for combined IgM/IgG.

FDA determined that the Anti-SARS-CoV-2 Rapid Test may be effective for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human plasma from anticoagulated blood (Heparin/EDTA/sodium citrate) or serum, and that the known and potential benefits of the test outweigh the known and potential risks for its use, based on the information available to the Agency at the time of that determination, including clinical performance data submitted by Autobio. Based on the results of new testing, FDA has determined that the Anti-SARS-CoV-2 Rapid Test does not meet current clinical performance estimates for serology tests that are generally necessary to satisfy the effectiveness and risk/benefit standards for issuance of an EUA. Specifically, the Agency has concluded that it is unlikely that this test is effective in detecting SARS-CoV-2 IgM antibodies and that the known and potential benefits of its use do not outweigh the known and potential risks.
Therefore, the Agency believes that the criteria for issuance of an authorization are no longer met and is revoking the EUA.

As you know, after authorization of EUA for your device, its performance was evaluated at the National Institutes of Health’s (NIH) Frederick National Laboratory for Cancer Research (FNLCR), part of the National Cancer Institute (NCI), using a well-characterized sample panel of 30 positive and 80 negative human plasma and serum specimens (referred to herein as the NCI evaluation). The evaluation was performed on June 24, 2020. As we first explained to you on July 6, 2020, the IgM sensitivity reported in the NCI study was 50% (15/30), while the IgM sensitivity in your device’s labeling is 85.43% (346/405) for all samples collected regardless of time since symptom onset, and 95.7% (289/302) for samples collected 15 or more days after symptom onset. FDA requested that you reply with information adequate to demonstrate that the health risks posed by the device performing differently than the labeled performance can be adequately mitigated/addressed in a timely manner.

On July 8, 2020, you provided a written response that summarized your investigations into the poor observed IgM performance in the NCI evaluation and proposed different potential mitigations. You proposed that a combination of factors could have contributed to the low IgM PPA/sensitivity observed in the NCI evaluation, as follows:

1. You proposed that the device’s [b] (4) such that it is possible that [b] (4) scenario, you proposed that [b] (4) You proposed that [b] (4)

2. You indicated that the SARS-CoV-2 [b] (4) domain was selected as a capture antigen for the device to focus on an IgM detection window in an early and acute infection period defined as two-to-three weeks after symptom onset. Other antigens such as the [b] (4) were rejected during test design based on indications that these antigens would likely extend IgM detection beyond the three-week period that you considered desirable for the test.

3. You noted that the average number of days post symptom onset for the 15 false negative samples was 29.9 days, and that the NCI samples contained low IgM titers (100 and 400). [b] (4)

You also cited other independent investigations in support of your test’s performance. This included tables and figures taken from the following publications:

- The Lassamiriére, et al pre-print (medRxiv 2020.04.09.20056325) included data from your test on a panel of 30 positive serum samples from PCR positive patients and 32 negative serum samples. Your test’s performance was only summarized for IgM/IgG combined, and so the article does not directly address IgM detection concerns.
The Demey B, et al. article (J Infect. 2020;81(2):e6-e10.) described a study serially testing 22 PCR positive patients with your test up to 24 days after symptom onset. Table 1 reported Antobio test IgM sensitivity up to 86.36% (19/22 subjects) on day 14 through day 24 after symptom onset. The Candel FJ, et al. article (Rev Esp Quimioter. 2020;33(4):258-266.) described a study in samples tested from 35 PCR positive patients between days 16 – 48 after symptom onset. In this study, your test’s IgM detection > 15 days after symptom onset was 74% (26/35).

You also cited data from other sources:
(b) (4)

The additional information you provided represents an assortment of data from studies with varying levels of documentation and rigor. Based on the limited information available, we were unable to fully assess these studies. Some data were derived from serially sampling the same PCR positive individuals over time to assess IgM detection, and some appears to be from testing single samples collected from unique individuals, similar to the studies described in the authorized labelling. In the additional studies, IgM detection for samples collected more than 14 days after symptom onset ranged from 74% - 86%. This is higher than the performance observed with the NCI sample set; however, this is significantly lower than IgM performance reported in the authorized labeling when considering the similar subset of samples collected 15 or more days after symptom onset (i.e., IgM PPA 95.7%, 289/302, 95% CI: 92.8 - 97.5%).

In your July 8 email, you proposed the following mitigations:
1. You proposed to modify (b)(4) the instructions for use to reduce the likelihood of (b)(4) You proposed to re-test the NCI panel with the same device lot (b)(4)
2. You proposed to re-design the plastic cassette housing to (b) (4)
3. You indicated that you could re-design (b) (4)

On July 16, 2020, you also proposed the following possible revisions to the instructions for use (b)(4)
1. Revising the (b)(4)
2. Revising the intended use to indicate that the IgM portion of the device is specifically designed “for
the detection of IgM in the early stages of the disease process and not during the rehabilitation stages.”

Your proposed actions do not adequately address FDA concerns regarding the authorized device, as discussed below.

Your proposal to modify the package insert would not ensure that the high IgM false negative rate would not continue to occur during clinical use.

Even assuming your theory were correct, this would indicate a design flaw that makes the test prone to error and that would require consistent attention and action by the end user to avoid false negatives with low titer positive samples that are close to the test cutoff. You have not provided adequate evidence to demonstrate that the proposed labeling changes would mitigate the risks to individuals and the public health as a result of false negative IgM results.

Further, your proposal to modify the intended use language is not consistent with the intended use of the currently authorized device, and so is not appropriate. You proposed to indicate that the IgM portion of the device is specifically designed for the detection of IgM in the early stages of disease. This intended use language could be misinterpreted as a claim to aid in the diagnosis of early disease. In contrast, the intended use language of SARS-CoV-2 antibody tests includes the following statements that contraindicate the use of these tests to diagnose early disease:

- [The test] should not be used to diagnose acute SARS-CoV-2 infection.
- The sensitivity of [the test] after early infection is unknown.

The other actions you proposed would be considered a re-design of the device. These changes are significant design modifications that can affect both the sensitivity and specificity, particularly the change to the capture antigen, which alters the operating principle of the device. Modifications such as these would need to be validated. As such, these proposed mitigations would not address, in a timely manner, the concerns with the device as currently authorized, and it is unclear whether these changes would successfully improve the performance of the device if you were to proceed with attempts to implement and validate these changes.

In short, the information you have provided does not address our concerns about the performance issues observed with your device, and we are unaware of any other currently available information that resolves these concerns.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20903

www.fda.gov
Conclusion

After consideration of the totality of scientific evidence available to the Agency, including all of your submissions, FDA has determined under section 564(g)(2)(B) that the criteria for issuance of emergency authorization in section 564(c) of the Act are no longer met for the Anti-SARS-CoV-2 Rapid Test. Under section 564(c)(2) an EUA may be issued only if FDA concludes it is reasonable to believe the product may be effective and the known and potential benefits outweigh the known and potential risks. Given the poor device performance regarding IgM sensitivity observed in the NCI evaluation after authorization of your device, FDA has concluded it is not reasonable to believe the product may be effective in detecting IgM antibodies to SARS-CoV-2 or that the known and potential benefits of your device outweigh its known and potential risks. In addition, based on the same information and the risks to public health from false test results, FDA has concluded under section 564(g)(2)(C) that other circumstances make revocation appropriate to protect the public health or safety.

Accordingly, FDA revokes EUA200349 for the Anti-SARS-CoV-2 Rapid Test, pursuant to section 564(g)(2)(B) and (C) of the Act. As of the date of this letter, the Anti-SARS-CoV-2 Rapid Test that was authorized by FDA for emergency use under EUA200349 is no longer authorized by FDA. As such, you are no longer authorized to distribute the Anti-SARS-CoV-2 Rapid Test. If you would like to work with FDA to resolve these issues, you may address the issues identified above and continue to work with us through a new pre-EUA or EUA request. In the event you submit a new notification to FDA for this test, or a notification for a re-designed and/or new test, note that FDA does not intend to place that test on the Section IV.D notification list, unless and until an EUA has been issued for such test.

If you have questions about this letter, please email Ellen Flannery, Deputy Center Director for Policy, Center for Devices and Radiological Health, at Ellen.Flannery@fda.hhs.gov.

Sincerely,

/s/

RADM Denise M. Hinton  
Chief Scientist  
Food and Drug Administration
July 21, 2020

To Manufacturers and Other Stakeholders:

This letter is to notify you of the revocation of the Emergency Use Authorization (EUA) issued April 28, 2020, for emergency use of certain in vitro diagnostic SARS-CoV-2 Antibody Tests\(^1\) intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, by detecting antibodies (IgG, or IgG and IgM, or total) to SARS-CoV-2 in human plasma and/or serum.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revised or revoked when the criteria under section 564(b)(1) of the Act no longer exist, the criteria under section 564(g) of the Act for issuance of such authorization are no longer met, or other circumstances make such revision or revocation appropriate to protect the public health or safety.

FDA has determined that circumstances make revocation of this EUA appropriate to protect the public health or safety. Any SARS-CoV-2 Antibody Tests added to the list of authorized devices in Appendix A of the April 28, 2020, letter of authorization would have been authorized for: (1) human plasma and/or serum samples only, (2) use only at laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform moderate or high complexity tests, and (3) the detection of IgG only, IgG and IgM, or total antibodies (i.e., not for the detection and differentiation of IgA from other immunoglobulins). To date, no device has been listed in Appendix A.

Based on information and experience since issuance of the umbrella EUA, FDA has determined that circumstances support revocation of the umbrella EUA so that FDA may issue individual EUAs. Individual EUAs will allow for broader indications and scopes of authorization, individualized conditions of authorization to address any issue unique to a specific test, and more streamlined EUA amendments, such as additional uses that would not fall under this umbrella EUA. Accordingly, FDA has decided to revoke this EUA. Instead, FDA will issue individual EUAs for SARS-CoV-2 Antibody Tests that meet the requisite EUA statutory criteria.

FDA has determined that circumstances make revocation of this EUA appropriate to protect the public health or safety for purposes of section 564(g)(2)(C) of the Act.

\(^1\) The SARS-CoV-2 Antibody Tests eligible for authorization under this EUA were Lateral Flow or Enzyme-linked immunosorbent assay (ELISA) tests that had been evaluated in an independent validation study performed at the National Institutes of Health’s (NIH) National Cancer Institute (NCI), or by another government agency designated by FDA.
Accordingly, pursuant to section 564(g)(2) of the Act, FDA revokes the EUA issued on April 28, 2020.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

/s/

RADM Denise M. Hinton
Chief
Scientist
Food and Drug Administration

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2020-21952 Filed: 10/2/2020 8:45 am; Publication Date: 10/5/2020]